Subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings, Guangzhou Baiyunshan Pharmaceutical Holdings Chinese Medicine, has received the notice of approval for clinical trials of drugs.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Hanfang Modern Medicine Co., Ltd. (referred to as "Guangzhou Baiyunshan Pharmaceutical Holdings Hanfang"), has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration recently. It is reported that on October 22, 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Hanfang submitted an application for clinical trials of LBZ-18 extract and its formulation LBZ-18 oral emulsion to the National Medical Products Administration, and the application was accepted on October 28, 2024. LBZ-18 oral emulsion is a class 1.2 innovative traditional Chinese medicine developed independently by Guangzhou Baiyunshan Pharmaceutical Holdings Hanfang, with the main function of invigorating qi and strengthening spleen, used for the treatment of cancer-related fatigue in cancer patients. As of the date of this announcement, Guangzhou Baiyunshan Pharmaceutical Holdings Hanfang has invested approximately RMB 29.36 million (unaudited) in the above-mentioned drug development project.